Latest Articles
More Evidence Links Physical Activity With Improved Cancer Survival, New ACS Study Finds | Newswise - Newswise
More Evidence Links Physical Activity With Improved Cancer Survival, New ACS Study Finds | Newswise Newswise
Published: May 20, 2025, 11:30 p.m.
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification - Nature
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification Nature
Published: May 20, 2025, 7:23 p.m.
Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection - Nature
Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection Nature
Published: May 18, 2025, 12:45 p.m.
Serous Borderline Ovarian Tumor and Extensive Abdominopelvic Endometriosis Mimicking Advanced Epithelial Ovarian Cancer in a Postmenopausal Patient - Frontiers
Serous Borderline Ovarian Tumor and Extensive Abdominopelvic Endometriosis Mimicking Advanced Epithelial Ovarian Cancer in a Postmenopausal Patient Frontiers
Published: May 16, 2025, 7:47 p.m.
Georgia Lawmakers Agree To Shield Bayer From Roundup Cancer Lawsuits - AboutLawsuits.com
Georgia Lawmakers Agree To Shield Bayer From Roundup Cancer Lawsuits AboutLawsuits.com
Published: May 15, 2025, 3 p.m.
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer TipRanks
Published: May 15, 2025, 4:53 a.m.
Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis - Nature
Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis Nature
Published: May 15, 2025, 12:37 a.m.
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients Stock Titan
Published: May 14, 2025, 8:10 p.m.
VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer - Healio
VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer Healio
Published: May 14, 2025, 8:04 p.m.
Bindi Irwin Undergoes 14 Endometriosis Lesions Excised, and Other Surgeries: Can Endometriosis Lesions Be Cancerous? - MSN
Bindi Irwin Undergoes 14 Endometriosis Lesions Excised, and Other Surgeries: Can Endometriosis Lesions Be Cancerous? MSN
Published: May 14, 2025, 6:01 p.m.
Link copied to clipboard!